The value of blood cytokines and chemokines in assessing COPD

  • Eric S. Bradford (Creator)
  • Sean Jacobson (Creator)
  • Jason Varasteh (Creator)
  • Alejandro Comellas (Creator)
  • Prescott G. Woodruff (Contributor)
  • Wanda K. O'Neal (Contributor)
  • Dawn L. DeMeo (Creator)
  • Xingnan Li (Contributor)
  • Victor Kim (Creator)
  • Michael H. Cho (Creator)
  • Peter J. Castaldi (Creator)
  • Craig P. Hersh (Creator)
  • E. K. Silverman (Creator)
  • James D. Crapo (Creator)
  • Katerina Kechris (Creator)
  • Russell Bowler (Creator)
  • Alejandro Comellas (Creator)
  • Wanda K. O’Neal (Creator)
  • Dawn Demeo (Creator)
  • Peter Castaldi (Creator)
  • Craig P. Hersh (Creator)
  • Edwin Silverman (Creator)
  • James Crapo (Creator)
  • Russell Bowler (Creator)

Dataset

Description

Abstract Background Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers. Methods We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs). Results Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3–5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements. Conclusion When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone. Trial registration COPDGene (ClinicalTrials.gov Identifier: NCT02445183 ). Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) ( ClinicalTrials.gov Identifier: NCT 01969344 ).
Date made available2017
Publisherfigshare
  • The value of blood cytokines and chemokines in assessing COPD

    Bradford, E., Jacobson, S., Varasteh, J., Comellas, A. P., Woodruff, P., O'Neal, W., DeMeo, D. L., Li, X., Kim, V., Cho, M., Castaldi, P. J., Hersh, C., Silverman, E. K., Crapo, J. D., Kechris, K. & Bowler, R. P., Oct 24 2017, In: Respiratory Research. 18, 1, p. 180 1 p.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    79 Scopus citations

Cite this